|Last Price$1.62||Day Change (%)-6.90%|
|Open Price$1.75||Day Change ($)-0.12|
|Day Range1.60–1.75||52-Week Range1.60–8.41|
As of Tue 09/16/2014 04:18 PM EST | USD
Exelixis Announces Results from the COMET-1 Phase 3 Pivotal Trial of Cabozantinib in Men with Metastatic Castration-Resistant Prostate Cancer
UPDATE: Apple, Tesla hit intraday records; Possible breach at Home Depot
UPDATE: Apple, Tesla hit intraday records; Conn's falls
U.S. stocks: Futures climb ahead of ISM data
UPDATE: U.S. stocks: Futures climb ahead of ISM data
The lack of early success in its lead drug's cancer trial scares the market, but we see a buying opportunity.
Lack of competitive advantages may mean these companies aren't the bargains they seem to be.
We see opportunity as fleeing investors trigger an irrational sell-off.
Morningstar analysts see pharmaceuticals as 2010's hot zone for mergers and acquisitions.